Early-Stage drug trial for rare lung disease halted before completion
NCT ID NCT02363946
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-phase study tested a drug called ARC-AAT in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal was to check safety and how the drug affects levels of a key protein. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Melbourne, Victoria, 3004, Australia
-
Research Site 2
Homburg, Germany
-
Research Site 3
Leiden, 2333ZA, Netherlands
-
Research Site 4
Edgbaston, Birmingham, B15 2WB, United Kingdom
Conditions
Explore the condition pages connected to this study.